Industry Overview

US animal vaccine market was valued at $4,396.3 million in 2025 and is projected to reach $8,844.3 million by 2035, growing at a CAGR of 7.3% during the forecast period (2026–2035). The US animal vaccine market is witnessing steady expansion, supported by rising livestock production, increasing companion animal ownership, and growing awareness regarding preventive animal healthcare. The market is driven by stringent regulatory frameworks governing animal health and food safety, alongside continuous advancements in veterinary biotechnology. Vaccination programs are increasingly recognized as cost-effective strategies to prevent infectious diseases, improve herd productivity, and reduce economic losses in commercial farming operations. Growing demand for high-quality animal protein, including poultry, pork, and beef, has reinforced the importance of preventive vaccination programs across commercial farms. At the same time, increasing pet humanization trends are boosting demand for advanced vaccines targeting companion animals. Technological innovation, including recombinant and DNA-based vaccines, is transforming the landscape by offering improved safety, enhanced immune response, and better disease coverage. As biosecurity concerns and zoonotic disease risks continue to rise, animal vaccination remains a critical pillar of veterinary public health in the United States.

Market Dynamics

Rising Focus on Livestock Productivity and Food Safety

The United States maintains one of the largest commercial livestock industries globally, necessitating structured vaccination programs to prevent outbreaks of infectious diseases. Increasing regulatory oversight from agencies such as the United States Department of Agriculture supports robust animal health monitoring and vaccination compliance. Disease prevention initiatives in swine, poultry, and cattle farming are encouraging adoption of advanced vaccines to minimize mortality, improve feed efficiency, and ensure export-quality meat production.

Growing Companion Animal Healthcare Expenditure

Rising pet adoption rates and increasing expenditure on veterinary care are significantly contributing to market growth. Pet owners are increasingly prioritizing preventive healthcare, including routine immunization schedules for dogs and cats. Expanding availability of combination vaccines and improved distribution through veterinary clinics and animal hospitals are strengthening vaccine uptake in the companion animal segment.

Advancements in Vaccine Technologies

Technological innovation is accelerating the shift from traditional killed and live attenuated vaccines to recombinant, vectored, and DNA-based platforms. These next-generation technologies offer improved safety profiles, targeted immune responses, and reduced adverse reactions. Biopharmaceutical companies are investing heavily in research and development to introduce multi-strain and disease-specific vaccines that address emerging animal health challenges.

Market Segmentation

• Based on the type, the market is segmented into porcine vaccines, poultry vaccines, livestock vaccines, aquaculture vaccines, companion animal vaccines, and other animal vaccines.
• Based on the technology, the market is segmented into live attenuated vaccine, killed/inactive vaccine, recombinant vaccine, vectored vaccine, subunit vaccine, DNA vaccine, chimeric vaccine, and others.

Companion Animal Vaccines Segment to Lead the Market with the Largest Share

The companion animal vaccines segment is expected to hold the largest share of the US animal vaccine market, driven by high pet ownership rates and growing awareness of preventive healthcare. Routine immunization programs for dogs and cats are well-established across veterinary practices nationwide. Increased spending on premium veterinary services, expanding pet insurance penetration, and the rising trend of pet humanization are further strengthening demand for advanced and combination vaccines. As regulatory guidelines mandate core vaccinations such as rabies, the segment is anticipated to maintain a dominant position in the market.

Recombinant and Advanced Vaccine Technologies Driving Innovation

Recombinant and vectored vaccines are gaining strong traction in the US animal vaccine market due to their improved safety profiles, targeted immune responses, and reduced risk of reversion to virulence. These advanced technologies are increasingly adopted in both livestock and companion animal applications. While live attenuated and inactivated vaccines continue to dominate in terms of volume, ongoing research and development investments are accelerating the commercialization of next-generation vaccine platforms. This technological shift is expected to enhance disease control efficiency and support long-term market growth.

Market Players Outlook

The major companies operating in the US animal vaccine market include Elanco Animal Health Incorporated, Merck & Co., Inc., Neogen Corporation, Phibro Animal Health Corporation, Zoetis Inc., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.

Recent Development

• In July 2025, Zoetis expanded its livestock vaccine portfolio in the United States with the introduction of an advanced multivalent swine vaccine designed to improve herd immunity and production performance.
• In May 2025, Merck Animal Health strengthened its recombinant vaccine pipeline through expanded R&D initiatives targeting emerging livestock and companion animal diseases across the US market.
• In March 2025, Elanco Animal Health announced strategic investments in next-generation vaccine technologies to enhance disease prevention solutions for both poultry and companion animals.

The Report Covers

• Market value data analysis of 2025 and forecast to 2035.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the US animal vaccine
• Based on the availability of data, information related to new products and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.